April 7th JinYao Pharmaceutical (600488) Dragon and Tiger List Data

robot
Abstract generation in progress

Securities Star News: According to the trading public information released by the Shanghai and Shenzhen Stock Exchanges on April 7, 2026, JinYao Pharmaceutical (600488) was listed on the Dragon and Tiger List after its closing price deviated by a total of 100% within 10 consecutive trading days with price limit restrictions. This is the fifth time it has appeared on the list in the past five trading days.

As of the close on April 7, 2026, JinYao Pharmaceutical (600488) closed at 7.67 yuan, up 10.04%, with 7 consecutive daily limit-ups, a turnover rate of 16.15%, a trading volume of 1.7635 million lots, and a transaction amount of 1.32B yuan.

Securities Knowledge: The Dragon and Tiger List is the public information of competitive bidding transactions disclosed by the stock exchanges. Stocks appearing on the Dragon and Tiger List are the most active stocks of the day and are key data points for investors’ daily focus. The exchange publishes the top five seats by buy and sell amounts for the day, with some seats representing special significance, such as institutional dedicated seats (funds, broker proprietary trading, social security, broker wealth management, insurance institutions, leased seats for insurance companies, QFII dedicated seats, etc.), which are dedicated channels and seats for institutional investors buying and selling securities. The Shenzhen-Hong Kong Stock Connect dedicated seats and Shanghai-Hong Kong Stock Connect dedicated seats are trading seats for northbound funds.

The above content is compiled from public information by Securities Star, generated by AI algorithms (Wang Xin Suan Bei 310104345710301240019), and does not constitute investment advice.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments